SUPPLEMENTARY MATERIAL

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

Authors: Jeffrey Frankel, MD,1 David Staskin, MD,2 Susann Varano, MD,3 Michael Kennelly, MD,4 Diane K. Newman, DNP, ANP-BC,5 Matt T. Rosenberg, MD,6 Rachael A. Jankowich, RN, MSN,7* Denise Shortino, MS,7* Paul N. Mudd Jr, PharmD, MBA,7*

Cynthia J. Girman, DrPH, FISPE8

1Seattle Urology Research Center, Seattle, WA, USA; 2Tufts University School of Medicine, Boston, MA, USA; 3Clinical Research Consulting, Milford, CT, USA; 4Carolinas Medical Center, Charlotte, NC, USA; 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 6Mid-Michigan Health Centers, Jackson, MI, USA; 7Urovant Sciences, Irvine, CA, USA; 8CERobs Consulting, LLC, Chapel Hill, NC, USA

*At the time the study was conducted.

Corresponding Author: Cynthia J. Girman, DrPH, FISPE

CERobs Consulting, LLC
2612 Lumina Avenue North
Wrightsville Beach, NC 28480

cindy.girman@cerobs.com

1-910-679-8023
Supplementary Table 1. Change From Baseline at Week 12 in Average Daily Number of Micturitions, Urgency Episodes, and UUI Episodes by PGI-Change* (Pooled Across Treatment Groups)

|                          | N   | Mean Change (SD) | Mean % Change (SD) | Median Change | Median % Change |
|--------------------------|-----|------------------|--------------------|---------------|-----------------|
| **Micturitions**         |     |                  |                    |               |                 |
| Much better              | 430 | −2.49 (2.32)     | −21.51 (18.48)     | −2.29         | −21.86          |
| Moderately better        | 303 | −1.95 (2.76)     | −15.65 (23.16)     | −2.00         | −18.18          |
| A little better          | 337 | −1.68 (2.58)     | 0.23 (241.30)      | −1.50         | −12.95          |
| No change or worse       | 263 | −0.70 (2.74)     | −4.71 (19.31)      | −0.57         | −4.96           |
| **Urgency episodes**     |     |                  |                    |               |                 |
| Much better              | 430 | −3.74 (3.38)     | −52.62 (41.30)     | −3.15         | −60.89          |
| Moderately better        | 303 | −2.76 (3.76)     | −27.64 (123.32)    | −2.29         | −35.00          |
| A little better          | 337 | −2.19 (3.44)     | −15.45 (112.47)    | −1.68         | −24.14          |
| No change or worse       | 263 | −0.95 (3.49)     | −8.15 (44.50)      | −0.57         | −8.83           |
| **UUI episodes†**        |     |                  |                    |               |                 |
| Much better              | 341 | −2.54 (2.24)     | −77.87 (60.57)     | −2.00         | −93.17          |
| Moderately better        | 227 | −1.71 (2.46)     | −45.83 (65.67)     | −1.33         | −64.49          |
| A little better          | 272 | −1.47 (2.16)     | −33.55 (74.73)     | −1.00         | −44.12          |
| No change or worse       | 191 | −0.69 (2.35)     | 6.40 (159.99)      | −0.61         | −22.31          |

FAS, full analysis set; FAS-I, FAS for incontinence; PGI-C, Patient Global Impression of Change; UUI, urge urinary incontinence.

*Presented in the FAS (all randomized patients who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement).

†Presented in the FAS-I (all randomized patients who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline measurement for UUI episodes).